Patents Assigned to Amgen
  • Methods of using conjugated toxin peptide therapeutic agents
    Patent number: 7910102
    Abstract: Disclosed is a composition of matter comprising an OSK1 peptide analog, and in some embodiments, a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises the composition and a pharmaceutically acceptable carrier. Also disclosed are DNAs encoding the inventive composition of matter, an expression vector comprising the DNA, and host cells comprising the expression vector. Methods of treating an autoimmune disorder and of preventing or mitigating a relapse of a symptom of multiple sclerosis are also disclosed.
    Type: Grant
    Filed: October 25, 2007
    Date of Patent: March 22, 2011
    Assignee: Amgen Inc.
    Inventors: John K. Sullivan, Joseph G. McGivern, Leslie P. Miranda, Hung Q. Nguyen, Kenneth W. Walker, Shaw-Fen Sylvia Hu, Colin V. Gegg, Jr., Taruna Arora Khare, Beverly S. Adler, Francis H. Martin
  • AURORA KINASE MODULATORS AND METHOD OF USE
    Publication number: 20110065709
    Abstract: The present invention relates to chemical compounds having a general formula I wherein A1-5 and 7-8, D?, L1, L2, R1, R3, R6-8, n and o are defined herein, and synthetic intermediates, which are capable of modulating the activity of Aurora kinase proteins and, thereby, influencing various disease states and conditions related to the activities of Aurora kinases. For example, the compounds are capable of influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.
    Type: Application
    Filed: March 19, 2009
    Publication date: March 17, 2011
    Applicant: Amgen Inc.
    Inventors: Ryan White, Jason Human
  • ANTI IgE ANTIBODIES
    Publication number: 20110064726
    Abstract: The present invention relates to novel human antibodies specifically directed against human immunoglobulin E (anti-IgE). The present invention also relates to pharmaceutical compositions and methods for treating asthma, in particular allergic asthma, as well as other IgE-mediated disorders including allergic rhinitis and food allergies.
    Type: Application
    Filed: November 24, 2010
    Publication date: March 17, 2011
    Applicants: PFIZER INC., AMGEN FREMONT INC.
    Inventors: Wai Liu, Mike Yeadon, Isabelle de Mendez, Alison Logan, Gerald F. Casperson, Arvind Rajpal, Mark A. Moffat, Wei Liao, Caroline Brown, Nurten Beyaz-Kavuncu, Judith Diaz-Collier, Sirid-Aimee Kellermann
  • Humanized anti-amyloid antibody
    Patent number: 7906625
    Abstract: Compositions for treating neurodegenerative or amyloidgenic disorders such as Alzheimer's disease (AD) are provided. More particularly, humanized anti-amyloid-beta antibodies, compositions containing such antibodies, corresponding nucleic acids, vectors and host cells, and methods of making such antibodies are provided.
    Type: Grant
    Filed: January 23, 2006
    Date of Patent: March 15, 2011
    Assignee: Amgen Inc.
    Inventors: Wenyan Shen, Anja L. Biere-Citron
  • STABILIZED PROTEIN COMPOSITIONS
    Publication number: 20110060290
    Abstract: Stabilized compositions of specific binding agents to RANKL, specific binding agents to TNF, and/or specific binding agents to IL-1R1 in containers are provided. Methods of making and using such compositions are also provided.
    Type: Application
    Filed: February 5, 2009
    Publication date: March 10, 2011
    Applicant: Amgen Inc.
    Inventors: Roberta Bonk, Mingda Eu, Amy Huinker, Monica Pallitto, Margaret Ricci, Nicole Stackhouse
  • OXAZOLE COMPOUNDS COMPOSITIONS AND METHODS OF USE
    Publication number: 20110060011
    Abstract: The present invention relates generally to compounds represented in Formula (I), pharmaceutical compositions comprising them and methods of treating of diseases or disorders such as cancer.
    Type: Application
    Filed: March 13, 2009
    Publication date: March 10, 2011
    Applicant: Amgen Inc.
    Inventors: Matthew Brown, Michael Johnson
  • Antigen binding proteins that bind PAR-2
    Publication number: 20110059063
    Abstract: The present invention provides compositions and methods relating to or derived from anti-PAR-2 antibodies. In particular embodiments, the invention provides human antibodies that bind PAR-2, PAR-2-binding fragments and derivatives of such antibodies, and PAR-2-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having PAR-2-related disorders or conditions.
    Type: Application
    Filed: June 26, 2008
    Publication date: March 10, 2011
    Applicant: Amgen Inc.
    Inventors: G. Duke Virca, Shaw-Fen Sylvia Hu
  • Human Anti-OPGL Neutralizing Antibodies as Selective OPGL Pathway Inhibitors
    Publication number: 20110052604
    Abstract: Monoclonal antibodies and hybridomas producing them that interact with osteoprotegerin ligand (OPGL) are provided. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are also provided. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are further provided.
    Type: Application
    Filed: May 18, 2010
    Publication date: March 3, 2011
    Applicant: AMGEN, INC.
    Inventors: William J. Boyle, Eugene Medlock, John J. Sullivan, Robin L. Elliott, Frank Martin, Haichun Huang
  • IL-17RA-IL-17RB ANTAGONISTS AND USES THEREOF
    Publication number: 20110052600
    Abstract: The present invention relates to Interleukin-17 ligand and receptor family members and the discovery that IL-17 receptor A and IL-17 receptor C form a heteromeric receptor complex that is biologically active. Antagonists of the IL-17RA-IL-17RB heteromeric receptor complex are disclosed, as well as various methods of use.
    Type: Application
    Filed: February 20, 2009
    Publication date: March 3, 2011
    Applicant: AMGEN INC.
    Inventors: Alison L. Budelsky, Michael R. Comeau, Joel E. Tocker
  • Heterocyclic modulators of PKB
    Patent number: 7897619
    Abstract: The invention relates to heterocyclic compounds of Formula I and compositions thereof useful for treating diseases mediated by protein kinase B (PKB) where the variables have the definitions provided herein. The invention also relates to the therapeutic use of such compounds and compositions thereof in treating disease states associated with abnormal cell growth, cancer, inflammation, and metabolic disorders.
    Type: Grant
    Filed: July 16, 2008
    Date of Patent: March 1, 2011
    Assignee: Amgen Inc.
    Inventors: Qingping Zeng, Dawei Zhang, Guomin Yao, George E. Wohlhieter, Xianghong Wang, James Rider, Andreas Reichelt, Holger Monenschein, Fang-Tsao Hong, James R. Falsey, Celia Dominguez, Matthew P. Bourbeau, John G. Allen
  • ANTI-AMYLOID ANTIBODIES AND USES THEREOF
    Publication number: 20110044986
    Abstract: Compositions for treating neurodegenerative or amyloidogenic disorders such as Alzheimer's disease (AD) are provided. More particularly, anti-amyloid-beta antibodies, compositions containing such antibodies, corresponding nucleic acids, vectors and host cells, and methods of making such antibodies are provided.
    Type: Application
    Filed: December 19, 2008
    Publication date: February 24, 2011
    Applicant: Amgen Inc.
    Inventors: Anja Leona Biere-Citron, Frederick W. Jacobsen, Stephen J. Wood
  • MEASUREMENT OF PROTEIN USING INCLUSION BODY DRY WEIGHT
    Publication number: 20110045527
    Abstract: The present invention is directed to improved methods for efficiently producing recombinant proteins. More specifically, the invention relates to a process for calculating the protein in inclusion bodies before the refolding step in large scale recombinant protein production, thereby improving the efficiency of the refolding step and overall yield and quality of the sample protein.
    Type: Application
    Filed: July 9, 2008
    Publication date: February 24, 2011
    Applicant: AMGEN INC.
    Inventor: Roujian Zhang
  • Human Anti-IFN-gamma Neutralizing Antibodies as Selective IFN-gamma Pathway Inhibitors
    Publication number: 20110045537
    Abstract: This invention provides antibodies that interact with or bind to human interferon-gamma (IFN-?) and methods for treating IFN-? mediated diseases by administering a pharmaceutically effective amount of antibodies to IFN-?. Methods of detecting the amount of IFN-? in a sample using antibodies to IFN-? are also provided.
    Type: Application
    Filed: July 6, 2010
    Publication date: February 24, 2011
    Applicant: AMGEN INC.
    Inventors: Andrew A. Welcher, Hilary T. Chute, Yue-Sheng "Luke" Li, Haichun Huang
  • Alkyne-substituted pyridone compounds and methods of use
    Patent number: 7893061
    Abstract: The present invention comprises a new class of compounds capable of modulating the c-kit receptor and, accordingly, useful for treatment of c-kit mediated diseases, including various inflammatory, fibrotic and/or mast cell mediated diseases such as mastocytosis. The compounds have a general Formula I wherein A1-3, R1 and R3-6 are defined herein. The invention further comprises pharmaceutical compositions, methods for treatment of c-kit mediated diseases, and intermediates and processes useful for the preparation of compounds of the invention.
    Type: Grant
    Filed: July 13, 2007
    Date of Patent: February 22, 2011
    Assignee: Amgen Inc.
    Inventor: Ryan White
  • Response element regions
    Patent number: 7892733
    Abstract: Response element regions, DNA constructs comprising response element regions, host cells comprising response element regions, and methods of using response element regions are provided.
    Type: Grant
    Filed: April 22, 2005
    Date of Patent: February 22, 2011
    Assignee: Amgen Inc.
    Inventors: Christiaan J. M. Saris, Shamin Summer, Sharon X. Mu, Jill A. Crouse
  • Bisaryl-sulfonamides
    Patent number: 7893077
    Abstract: Compounds, compositions and methods are provided that are useful in the treatment or prevention of a condition or disorder mediated by PPAR? or PPAR?. In particular, the compounds of the invention modulate the function of PPAR? or PPAR?. The subject methods are particularly useful in the treatment and/or prevention of diabetes, obesity, hypercholesterolemia, rheumatoid arthritis and atherosclerosis.
    Type: Grant
    Filed: November 12, 2008
    Date of Patent: February 22, 2011
    Assignee: Amgen Inc.
    Inventors: Philippe Bergeron, Christopher N. Farthing, Stuart D. Jones, John W. Liebeschuetz, Sarah E. Lively, Lawrence R. McGee, Sharon McKendry, David Sheppard, Stephen C. Young
  • Human Anti-NGF Neutralizing Antibodies as Selective NGF Pathway Inhibitors
    Publication number: 20110040076
    Abstract: This invention provides antibodies that interact with or bind to human nerve growth factor (NGF) and neutralize the function of NGF thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing NGF function, and particularly for treating NGF-related disorders (e.g., chronic pain) by administering a pharmaceutically effective amount of anti-NGF antibodies. Methods of detecting the amount of NGF in a sample using anti-NGF antibodies are also provided.
    Type: Application
    Filed: August 18, 2010
    Publication date: February 17, 2011
    Applicants: AMGEN INC., MEDAREX, INC.
    Inventors: Kenneth D. Wild, JR., James J.S. Treanor, Haichun Huang, Heather Inoue, Tie J. Zhang, Frank Martin
  • Antibodies that bind PAR-2
    Patent number: 7888482
    Abstract: The present invention provides compositions and methods relating to or derived from anti-PAR-2 antibodies. In particular embodiments, the invention provides antibodies that bind human PAR-2, PAR-2-binding fragments and derivatives of such antibodies, and PAR-2-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having PAR-2-related disorders or conditions.
    Type: Grant
    Filed: February 8, 2007
    Date of Patent: February 15, 2011
    Assignee: Amgen Inc.
    Inventors: George Duke Virca, Shaw-Fen Sylvia Hu
  • Antibodies to fibroblast growth factor-like polypeptides
    Patent number: 7887799
    Abstract: The present invention provides novel Fibroblast Growth Factor-like (FGF-like) polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, antibodies and methods for producing FGF-like polypeptides. Also provided for are methods for the diagnosis and treatment of diseases associated with FGF-like polypeptides.
    Type: Grant
    Filed: November 13, 2008
    Date of Patent: February 15, 2011
    Assignee: Amgen Inc.
    Inventors: Arlen Thomason, Benxian Liu
  • Host cells comprising alpha 1,2 mannosidase and culture methods thereof
    Patent number: 7888101
    Abstract: Improved host cells and culture methods involving overexpression of MAN1C1 activity to improve protein production are provided.
    Type: Grant
    Filed: December 6, 2006
    Date of Patent: February 15, 2011
    Assignee: Amgen Inc.
    Inventor: Christopher K. Crowell